Universitätsklinikum Münster

First report from the German COVID-19 autopsy registry (2022) von Stillfried S, Bülow RD, Röhrig R, Boor P, Böcker J, Schmidt J, Tholen P, et al. Journal article S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL (2022) Sabrina V, Michael B, Joerg A, Peter B, Wolf B, Susanne B, Thomas B, et al. Journal article Utility of the Repeat and Point Test for Subtyping Patients with Primary Progressive Aphasia (2022) Seckin M, Ricard I, Raiser T, Heitkamp N, Ebert A, Prix C, Levin J, et al. Journal article S3-Guideline: Diagnosis and Therapy of Hepatocellular Carcinoma (2022) Sabrina V, Michael B, Joerg A, Peter B, Wolf B, Susanne B, Thomas B, et al. Journal article Next-generation antibody-based therapies in neurology (2021) Ruck T, Nimmerjahn F, Wiendl H, Luenemann JD Journal article, Review article Combined resting state-fMRI and calcium recordings show stable brain states for task-induced fMRI in mice under combined ISO/MED anesthesia (2021) Pradier B, Wachsmuth L, Nagelmann N, Segelcke D, Kreitz S, Heß A, Pogatzki-Zahn EM, Faber C Journal article Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia (2021) Bazarbachi AH, Labopin M, Kroger N, Brecht A, Blaise D, Clausen J, Fanin R, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Conference contribution